- Home
- MSW vs TNXP Comparison
MSW vs TNXP Comparison
Compare MSW & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSW
- TNXP
- Stock Information
- Founded
- MSW 2012
- TNXP 2007
- Country
- MSW Hong Kong
- TNXP United States
- Employees
- MSW N/A
- TNXP N/A
- Industry
- MSW
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- MSW
- TNXP Health Care
- Exchange
- MSW NYSE
- TNXP Nasdaq
- Market Cap
- MSW N/A
- TNXP 71.6M
- IPO Year
- MSW 2024
- TNXP N/A
- Fundamental
- Price
- MSW $3.59
- TNXP $18.18
- Analyst Decision
- MSW
- TNXP Strong Buy
- Analyst Count
- MSW 0
- TNXP 2
- Target Price
- MSW N/A
- TNXP $585.00
- AVG Volume (30 Days)
- MSW 64.5K
- TNXP 2.6M
- Earning Date
- MSW 05-25-2025
- TNXP 03-18-2025
- Dividend Yield
- MSW N/A
- TNXP N/A
- EPS Growth
- MSW 18.78
- TNXP N/A
- EPS
- MSW 0.20
- TNXP N/A
- Revenue
- MSW $31,769,612.00
- TNXP $10,094,000.00
- Revenue This Year
- MSW N/A
- TNXP $84.08
- Revenue Next Year
- MSW N/A
- TNXP $126.94
- P/E Ratio
- MSW $17.66
- TNXP N/A
- Revenue Growth
- MSW 30.91
- TNXP 29.94
- 52 Week Low
- MSW $2.12
- TNXP $6.76
- 52 Week High
- MSW $10.58
- TNXP $672.00
- Technical
- Relative Strength Index (RSI)
- MSW N/A
- TNXP 48.95
- Support Level
- MSW N/A
- TNXP $12.80
- Resistance Level
- MSW N/A
- TNXP $31.87
- Average True Range (ATR)
- MSW 0.00
- TNXP 4.30
- MACD
- MSW 0.00
- TNXP 0.57
- Stochastic Oscillator
- MSW 0.00
- TNXP 22.53
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.